Continued FDA approval of iptacopan was contingent on 2-year trial data ...

A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...

Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...

Biogen has announced a definitive agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion, a move that would expand its presence in complement-mediated diseases, including ...

Akebia Therapeutics (NASDAQ:AKBA) used its R&D Day presentation to outline a strategy centered on expanding its commercial ...

Dianthus Therapeutics focuses on developing DNTH103, a next-gen complement inhibitor for severe autoimmune diseases, currently in trials for CIDP, gMG, and MMN. Despite promising in vitro results, ...

A research team at the Medical University of South Carolina reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that ...

The FDA granted accelerated approval to iptacopan (Fabhalta) for primary immunoglobulin A (IgA) nephropathy, a rare progressive disease where the immune system attacks the kidneys, Novartis announced ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal ...

In this interview, we spoke with Gloria Gerber, MD, a hematologist and assistant professor of medicine at Johns Hopkins University, about the evolution of treatment for paroxysmal nocturnal ...